Lv4
430 积分 2024-09-07 加入
Final Analysis of Consolidative Use of Radiotherapy to Block (CURB) Oligoprogression Trial - A Randomized Study of Stereotactic Body Radiotherapy for Oligoprogressive Metastatic Lung and Breast Cancers
1个月前
已完结
Efficacy and safety of immune checkpoint inhibitor rechallenge in individuals with hepatocellular carcinoma
1个月前
已关闭
New trials and results in systemic treatment of HCC
1个月前
已完结
Radiologic Response Assessment With RECIST 1.1 and mRECIST in Patients With Hepatocellular Carcinoma Treated With Atezolizumab Plus Bevacizumab
1个月前
已完结
Efficacy and safety of combined TACE-HAIC and targeted immunotherapy in primary liver cancer with portal vein tumor thrombus
2个月前
已完结
影像引导原发性肝癌消融指南（2023版）
2个月前
已完结
Imaging of Cardiac and Nonaortic Thoracic Vascular Trauma
6个月前
已完结
The “A-B-C” classification reveals outcome trajectories in patients with hepatocellular carcinoma under atezolizumab/bevacizumab
8个月前
已完结
Sequential therapies after atezolizumab plus bevacizumab or lenvatinib first-line treatments in hepatocellular carcinoma patients
10个月前
已完结
Phase 3 randomized, open-label, multicenter study of tremelimumab (T) and durvalumab (D) as first-line therapy in patients (pts) with unresectable hepatocellular carcinoma (uHCC): HIMALAYA
10个月前
已完结
皖公网安备34019202002308
